• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
 
Generic Name:  rosuvastatin
Trade Name:  Crestor
Date Designated:  02/14/2014
Orphan Designation:  For the treatment of pediatric homozygous familial hypercholesterolemia
Orphan Designation Status:  Designated/Approved
Marketing Approval Date:  05/27/2016 
Approved Labeled Indication:  An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis).
Exclusivity End Date:    05/27/2023 
Exclusivity Protected Indication* :  An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis).
iPR Pharmaceuticals, Inc.
1 MedImmune Way

Gaithersburg, Maryland 20878
United States

The sponsor address listed is the last reported by the sponsor to OOPD.
*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.
-
-